Emcure Pharmaceuticals reported a remarkable 63 percent increase in consolidated profit after tax (PAT) to Rs 197 crore for the quarter ended March 2025, underscoring its accelerating momentum. The Pune-based firm’s revenue surged nearly 20 percent year-on-year to Rs 2,116 crore, buoyed by strong performances in both domestic and international markets. The company’s domestic segment led growth, particularly in women’s health and cardiology, while strategic acquisitions and regulatory advances in Europe have strengthened its global footprint.